{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:06:13Z","timestamp":1771563973806,"version":"3.50.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The outcome for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) has improved, mostly based on the use of pediatric-inspired intensive protocols. Due to increasing disease resistance and treatment-related toxicity with age, further improvements are now expected from the expanding knowledge of ALL biology, more accurate risk stratification, and the early introduction of targeted small molecules and immunotherapy. In the last decade, the rate of AYA with B-cell precursor ALL with undetermined genetic drivers (\u201cB-other\u201d) has shrunk from 40% to fewer than 10%. The high-risk subgroup of Philadelphia-like ALL is the most frequent entity diagnosed in this age range, offering a multitude of potentially actionable targets. The timely and accurate identification of these targets remains challenging, however. Early minimal residual disease (MRD) monitoring has become a standard of care for the risk stratification and identification of patients likely to benefit from an allogeneic hematopoietic stem cell transplantation. Recently approved immunotherapies are moving frontline to eradicate MRD, to improve the outcome of high-risk patients, and, eventually, to reduce treatment burden. Comprehensive care programs dedicated to AYA with cancer aim at improving inclusion in specific clinical trials and at giving access to appropriate psychosocial support, fertility preservation, and survivorship programs.<\/jats:p>","DOI":"10.1182\/hematology.2022000336","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:08:48Z","timestamp":1670602128000},"page":"190-196","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["New developments in ALL in AYA"],"prefix":"10.1182","volume":"2022","author":[{"given":"Nicolas","family":"Boissel","sequence":"first","affiliation":[{"name":"Adolescent and Young Adult Hematology Unit, Saint-Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris, Institut de Recherche Saint-Louis, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"4","key":"2022120916075373500_hem2022000336C1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","volume":"132","author":"Boissel","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2022120916075373500_hem2022000336C2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome- negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"2022120916075373500_hem2022000336C3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of ALL in children vs adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2022120916075373500_hem2022000336C4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","article-title":"Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?","volume":"21","author":"Schiffer","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022120916075373500_hem2022000336C5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.13847","article-title":"Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003","volume":"172","author":"Hough","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2022120916075373500_hem2022000336C6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"24","key":"2022120916075373500_hem2022000336C7","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022120916075373500_hem2022000336C8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv"},{"issue":"17","key":"2022120916075373500_hem2022000336C9","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.3390\/jcm10173792","article-title":"Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia","volume":"10","author":"Iacobucci","year":"2021","journal-title":"J Clin Med"},{"issue":"16","key":"2022120916075373500_hem2022000336C10","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2022120916075373500_hem2022000336C11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.beha.2017.06.001","article-title":"How is the Ph-like signature being incorporated into ALL therapy?","volume":"30","author":"Maese","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"24","key":"2022120916075373500_hem2022000336C12","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.2021014723","article-title":"Concurrent CDX2 cis-deregulation and UBTF-ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL","volume":"139","author":"Passet","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2022120916075373500_hem2022000336C13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cncr.31848","article-title":"BCR\/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat?","volume":"125","author":"Chiaretti","year":"2019","journal-title":"Cancer"},{"issue":"35","key":"2022120916075373500_hem2022000336C14","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2017.77.3648","article-title":"New approaches to the management of adult acute lymphoblastic leukemia","volume":"36","author":"Bassan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"2022120916075373500_hem2022000336C15","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2017009845","article-title":"Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation","volume":"1","author":"Br\u00fcggemann","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2022120916075373500_hem2022000336C16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O'Connor","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"2022120916075373500_hem2022000336C17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.V122.21.552.552","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): results from the Group for Research on Adult ALL (GRAALL)","volume":"122","author":"Dhedin","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2022120916075373500_hem2022000336C18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","article-title":"Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"23 December","key":"2022120916075373500_hem2022000336C19","doi-asserted-by":"crossref","first-page":"782785","DOI":"10.3389\/fped.2021.782785","article-title":"Allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia: shifting indications in the era of immunotherapy","volume":"9","author":"Truong","year":"2021","journal-title":"Front Pediatr"},{"issue":"8","key":"2022120916075373500_hem2022000336C20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2022120916075373500_hem2022000336C21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2022120916075373500_hem2022000336C22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"2022120916075373500_hem2022000336C23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2022120916075373500_hem2022000336C24","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"8","key":"2022120916075373500_hem2022000336C25","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"issue":"13","key":"2022120916075373500_hem2022000336C26","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","article-title":"Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia","volume":"2","author":"Stein","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"2022120916075373500_hem2022000336C27","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"March","key":"2022120916075373500_hem2022000336C28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6 January","key":"2022120916075373500_hem2022000336C29","first-page":"804714","article-title":"Real-world multicenter experience in tumor debulking prior to blinatumomab administration in adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"11","author":"Bonifacio","year":"2021","journal-title":"Front Oncol"},{"key":"2022120916075373500_hem2022000336C30","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia: a real-world study by the GRAALL [published online ahead of print 10 March 2022]","author":"Cabannes-Hamy","journal-title":"Haematologica"},{"issue":"9","key":"2022120916075373500_hem2022000336C31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"2022120916075373500_hem2022000336C32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"suppl 1","key":"2022120916075373500_hem2022000336C33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2021-146393","article-title":"Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry","volume":"138","author":"John","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2022120916075373500_hem2022000336C34","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2022120916075373500_hem2022000336C35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"2022120916075373500_hem2022000336C36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022120916075373500_hem2022000336C37","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2022120916075373500_hem2022000336C38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2021-146944","article-title":"Safety and efficacy of menin inhibition in patients (Pts) with MLL-rearranged and NPM1 mutant acute leukemia: a phase (Ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101)","volume":"138","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"11 January","key":"2022120916075373500_hem2022000336C39","first-page":"796426","article-title":"Haematopoietic Stem cell transplantation in adolescents and young adults with acute lymphoblastic leukaemia: special considerations and challenges","volume":"9","author":"Calvo","year":"2021","journal-title":"Front Pediatr"},{"issue":"4","key":"2022120916075373500_hem2022000336C40","doi-asserted-by":"crossref","first-page":"pkaa025","DOI":"10.1093\/jncics\/pkaa025","article-title":"Late effects in survivors of adolescent and young adult acute lymphoblastic leukemia","volume":"4","author":"Muffly","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"23","key":"2022120916075373500_hem2022000336C41","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2007.10.8993","article-title":"Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls","volume":"25","author":"Hammond","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022120916075373500_hem2022000336C42","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.rbmo.2021.11.015","article-title":"In-vitro maturation and transplantation of cryopreserved ovary tissue: understanding ovarian longevity","volume":"44","author":"Silber","year":"2022","journal-title":"Reprod Biomed Online"},{"issue":"12","key":"2022120916075373500_hem2022000336C43","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2020007782","article-title":"Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia","volume":"137","author":"Chevillon","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2022120916075373500_hem2022000336C44","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.fertnstert.2021.03.004","article-title":"In vitro growth and maturation of primordial follicles and immature oocytes","volume":"115","author":"Telfer","year":"2021","journal-title":"Fertil Steril"},{"issue":"4","key":"2022120916075373500_hem2022000336C45","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1097\/HS9.0000000000000544","article-title":"Osteonecrosis in adults with acute lymphoblastic leukemia: an unmet clinical need","volume":"5","author":"Kuhlen","year":"2021","journal-title":"Hemasphere"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/190\/2021705\/190boissel.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/190\/2021705\/190boissel.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:09:10Z","timestamp":1670602150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/190\/493486\/New-developments-in-ALL-in-AYA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000336","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}